Biotech Companies in San Francisco Hiring Now 5/17/2023

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian's first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022.

Irregularities in the body's genetic coding to make proteins are linked to cancerous tumors. But most genetic material contains elements whose function isn’t clear.

Could abnormalities in non-coding material also impact a person’s health, or even be linked to cancers as well?

Lilly-Backed Nido Biosciences Launches with $109M to Target Neurological Diseases 5/15/2023

Astellas Wins FDA Approval for Hot Flash Treatment in Menopausal Women 5/15/2023

AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova 5/15/2023

Companies Bank on Psychedelics as Treatments for Mental Health Disorders 5/15/2023

Therapies for Rare Mitochondrial Diseases Begin to See Traction 5/15/2023

FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept 5/15/2023

Sarepta’s Duchenne Therapy Recommended for Accelerated Approval 5/13/2023

Experts from Newcastle University found the nervous system of people with post-COVID fatigue was underactive in three key areas. Fatigue is one of the most common symptoms of long COVID.

The breakthrough could lead to better treatment and tests to identify the condition and the team are already progressing the work having just started a trial.

Today, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication.

Bayer AG announced the inauguration of its new life science incubator dubbed "Co.Lab Cambridge" located in Kendall Square in Cambridge, U.S.. Bayer's Co.Lab Cambridge is specifically designed to support cutting-edge cell and gene therapies (CGT) entrepreneurs with access to Bayer's enterprise wide expertise in addition to state-of-the art laboratory and office space.

Vitamin D intake could reduce cancer mortality in the population by twelve percent - provided the vitamin is taken daily. This was the result of an evaluation of 14 studies of the highest quality conducted at the German Cancer Research Center with a total of almost 105,000 participants.

Vitamin D deficiency is widespread worldwide and is particularly common among cancer patients.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop.

Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive. For decades, scientists have attempted to develop drugs that selectively activate one type of opioid receptor to treat pain while not activating another type of opioid receptor linked to addiction. Unfortunately, those compounds can cause a different unwanted effect: hallucinations.

Regeneron Diversifies Portfolio as Eylea Revenue Takes a Hit 5/5/2023

AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation 5/5/2023

Novo Nordisk’s Hemophilia Hopeful Hits FDA Roadblock, Company Cuts Wegovy Supply 5/5/2023

Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations 5/5/2023